Trevi Therapeutics Inc (TRVI)

04:48 AM

Trevi Therapeutics Reports Q1 2025 Results and Updates - TipRanks

04:48 AM

04:02 AM

MetLife Investment Management LLC Purchases 19,857 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

04:02 AM

03:43 AM

Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings Call Highlights: Promising Trial Results and ... - Yahoo Finance

03:43 AM

May 08, 2025

Earnings call transcript: Trevi Therapeutics beats Q1 2025 EPS expectations - Investing.com

May 08, 2025

May 08, 2025

Trevi Therapeutics (TRVI): Promising Data and Strategic Advances | TRVI Stock News - GuruFocus

May 08, 2025

May 08, 2025

Trevi Therapeutics Inc (TRVI) Q1 2025 Earnings: EPS of -$0.09 Beats Estimate, Reports $10.3 Million Net Loss - GuruFocus

May 08, 2025

May 08, 2025

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates | TRVI Stock News - GuruFocus

May 08, 2025

May 08, 2025

Trevi Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates - Stock Titan

May 08, 2025

May 08, 2025

Barclays PLC Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 08, 2025

May 08, 2025

Market Insights: Trevi Therapeutics Inc (TRVI)’s Notable Gain of 1.22, Closing at 6.66 - DWinneX

May 08, 2025

May 07, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Rating of “Buy” from Analysts - Defense World

May 07, 2025

May 06, 2025

Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView

May 06, 2025

May 06, 2025

Invesco Ltd. Boosts Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 06, 2025

May 05, 2025

Renaissance Technologies LLC Acquires 29,700 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

May 05, 2025

May 04, 2025

Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday - Defense World

May 04, 2025

May 02, 2025

Trevi Therapeutics to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 8, 2025 - StreetInsider

May 02, 2025

May 01, 2025

Trevi Therapeutics to Report First Quarter 2025 Financial Result - GuruFocus

May 01, 2025

May 01, 2025

Trevi Therapeutics Inc [TRVI] Records 50-Day SMA of $5.77 - knoxdaily.com

May 01, 2025

May 01, 2025

Indo-Asian News Service - Indo-Asian News Service (IANS)

May 01, 2025

Apr 29, 2025

A look at TRVI’s current quarter earnings estimates - uspostnews.com

Apr 29, 2025

Apr 29, 2025

TRVI’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com

Apr 29, 2025

Apr 29, 2025

Quarterly Metrics: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX

Apr 29, 2025

Apr 29, 2025

SEC Form DEF 14A filed by Trevi Therapeutics Inc. - Quantisnow

Apr 29, 2025

Apr 29, 2025

JPMorgan Chase & Co. Boosts Stock Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Apr 29, 2025

Apr 28, 2025

Recent Insider Activity Suggests Potential Gains for Trevi Therapeutics Inc (TRVI) - knoxdaily.com

Apr 28, 2025

Apr 28, 2025

What is Trevi Therapeutics Inc (TRVI) Stock Return on Shareholders’ Capital? - Sete News

Apr 28, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 26, 2025

Geode Capital Management LLC Has $5.35 Million Position in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Apr 26, 2025

Apr 24, 2025

Quarterly Snapshot: Quick and Current Ratios for Trevi Therapeutics Inc (TRVI) - DWinneX

Apr 24, 2025

Apr 24, 2025

Stifel Nicolaus Remains a Buy on Trevi Therapeutics (TRVI) - The Globe and Mail

Apr 24, 2025

Apr 24, 2025

Trevi Therapeutics Inc (TRVI)’s results reveal risk - uspostnews.com

Apr 24, 2025

Apr 23, 2025

Stifel maintains Trevi Therapeutics stock Buy rating, $15 target By Investing.com - Investing.com Canada

Apr 23, 2025

Apr 14, 2025

12,000 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Acquired by Raymond James Financial Inc. - Defense World

Apr 14, 2025

Apr 14, 2025

American Century Companies Inc. Buys 24,153 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Apr 14, 2025

Apr 12, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Rating of “Buy” by Analysts - Defense World

Apr 12, 2025

Apr 10, 2025

Trevi Therapeutics Sees Unusually Large Options Volume (NASDAQ:TRVI) - Defense World

Apr 10, 2025

Apr 09, 2025

Trevi Therapeutics (NASDAQ:TRVI) Given Buy Rating at Needham & Company LLC - Defense World

Apr 09, 2025

Apr 07, 2025

Trevi Therapeutics at 24th Annual Needham: Strategic Advances in Cough Treatments - Investing.com Canada

Apr 07, 2025

Apr 04, 2025

Trevi Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Seeking Alpha

Apr 04, 2025

Apr 04, 2025

Prurigo Nodularis Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Celgene Crp., Novartis, Pfizer, Galderma, Genentech, Incyte Crp., Trevi Therapeutics, Vyne Therapeutics - The Globe and Mail

Apr 04, 2025

Apr 03, 2025

Trevi Therapeutics to Participate in Upcoming April Investor Conferences - The Malaysian Reserve

Apr 03, 2025

Apr 03, 2025

Trevi's Game-Changing Chronic Cough Treatment Takes Center Stage at 3 Major Healthcare Conferences - Stock Titan

Apr 03, 2025

Apr 03, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Sees Significant Growth in Short Interest - Defense World

Apr 03, 2025

Apr 01, 2025

Charles Schwab Investment Management Inc. Has $713,000 Stock Holdings in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Apr 01, 2025

Apr 01, 2025

What to expect from TRVI’s earnings report this quarter? - uspostnews.com

Apr 01, 2025

Mar 31, 2025

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones - Proactive financial news

Mar 31, 2025

Mar 31, 2025

Trevi Therapeutics advances cough treatment pipeline, eyes key clinical milestones | NASDAQ:TRVI - Proactive Investors

Mar 31, 2025

Mar 28, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World

Mar 28, 2025

Mar 26, 2025

Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock By Investing.com - Investing.com Australia

Mar 26, 2025

Mar 26, 2025

Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com

Mar 26, 2025

Mar 25, 2025

Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa

Mar 25, 2025

Mar 25, 2025

Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com

Mar 25, 2025

Mar 22, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript - Insider Monkey

Mar 22, 2025